The application of monoclonal antibodies like anti-CD20 and anti-HER2 antibodies can let macrophages exert antibody-dependent cellular cytotoxicity (ADCC), which underpins the anti-tumor activities of these drugs.18,32 Additionally, several interventions, including the activation of IRF (IFN Regulatory Factor) 7, blocking CD47 on tumor cells which interact with SIRPα (signal-regulatory protein α) mediating the “don’t eat me” signal, and inhibiting immune checkpoint molecule PD-L1, have shown promise in reprogramming TAMs towards an anti-tumor phenotype.33–36. This evidence concerns the gene SIRPA and neoplasm.